3-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.
November 09, 2020
Share
3-D Matrix, Ltd. (JASDAQ:7777) announced that it has entered into purchase agreement with returning investor, CVI Investments, Inc. for private placement of 561,700 shares at a price of ¥356 per share for gross proceeds of ¥199,965,200, 55,000 27th stock acquisition rights at a price of ¥291 per right for gross proceeds of ¥16,105,000, 10,000 28th stock acquisition rights at a price of ¥10 per right for gross proceeds of ¥100,000; for an aggregate gross proceeds of ¥216,070,200 on November 10, 2020. The company will receive money through third party allotment. The 27th stock acquisition rights can be exercisable to purchase 5,500,000 shares of the company at an exercise price of ¥356 per share and 28th stock acquisition rights can be exercise to purchase 1,000,000 shares of the company at an exercise price of ¥435 per share. The 27th stock acquisition rights can be exercised from November 27, 2020 to May 26, 2022 and 28th stock acquisition rights can be exercised from November 27, 2020 to November 26, 2024. The company incurred issuance expense of ¥25,000,000 in relation to the transaction. The transaction is expected to close on November 26, 2020. The transaction has been approved by the board of directors of the company.
3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.